EAU-EANM-ESTRO-ESUR-ISUP-SIOG前列腺癌指南2024更新第一部分:筛查、诊断与以治愈为目的的局部治疗
该指南由欧洲泌尿外科学会等多学科机构联合制定,基于2020年5月至2023年发表的英文文献更新,针对临床局限性前列腺癌的筛查、诊断与局部治疗给出推荐并标注推荐强度。推荐采用风险适应策略识别可能发生前列腺癌的男性,一般从50岁开始并结合个体化预期寿命;推荐使用多参数磁共振成像以避免不必要的活检;活检时建议联合靶向与区域穿刺。
要点
- 推荐使用多参数磁共振成像以避免不必要的前列腺穿刺活检。
- 前列腺特异性膜抗原正电子发射断层成像识别转移播散最敏感。
- 活检时建议联合靶向穿刺与区域穿刺。
核心结论
- 诊断、分期与治疗局限性前列腺癌的证据正快速演进,本指南体现前列腺癌管理的多学科性质。
研究设计与样本
- 由欧洲泌尿外科学会、欧洲核医学协会、欧洲放射肿瘤学会、欧洲泌尿生殖放射学会、国际泌尿病理学会与国际老年肿瘤学会联合制定;对2020年5月至2023年发表的英文新数据进行文献综述,更新指南并基于系统证据综述为每条推荐添加推荐强度评级。
诊断标准与关键数值
- 建议采用风险适应策略识别可能发生前列腺癌的男性,一般从50岁开始,并基于个体化预期寿命。
- 推荐使用多参数磁共振成像以避免不必要的活检。
- 当考虑活检时,应联合进行靶向穿刺与区域穿刺。
- 前列腺特异性膜抗原正电子发射断层成像识别转移播散最敏感。
- 对于低危前列腺癌以及国际泌尿病理学会分级分组2的特定有利中危患者,主动监测是适当的管理方式。
临床应用与阅片要点
- 对临床局限性前列腺癌,风险适应筛查一般从50岁开始并结合个体化预期寿命。
- 推荐多参数磁共振成像用于避免不必要活检;考虑活检时联合靶向与区域穿刺。
- 前列腺特异性膜抗原正电子发射断层成像为识别转移播散最敏感的技术。
- 中危患者可考虑大分割放疗;cN1患者应接受局部治疗联合长期强化激素治疗。
- 低危及特定有利中危(国际泌尿病理学会分级分组2)患者适合主动监测。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVE: The European Association of Urology (EAU)-European Association of Nuclear Medicine (EANM)-European Society for Radiotherapy and Oncology (ESTRO)-European Society of Urogenital Radiology (ESUR)-International Society of Urological Pathology (ISUP)-International Society of Geriatric Oncology (SIOG) guidelines provide recommendations for the management of clinically localised prostate cancer (PCa). This paper aims to present a summary of the 2024 version of the EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on the screening, diagnosis, and treatment of clinically localised PCa.
METHODS: The panel performed a literature review of all new data published in English, covering the time frame between May 2020 and 2023. The guidelines were updated, and a strength rating for each recommendation was added based on a systematic review of the evidence.
KEY FINDINGS AND LIMITATIONS: A risk-adapted strategy for identifying men who may develop PCa is advised, generally commencing at 50 yr of age and based on individualised life expectancy. The use of multiparametric magnetic resonance imaging in order to avoid unnecessary biopsies is recommended. When a biopsy is considered, a combination of targeted and regional biopsies should be performed. Prostate-specific membrane antigen positron emission tomography imaging is the most sensitive technique for identifying metastatic spread. Active surveillance is the appropriate management for men with low-risk PCa, as well as for selected favourable intermediate-risk patients with International Society of Urological Pathology grade group 2 lesions. Local therapies are addressed, as well as the management of persistent prostate-specific antigen after surgery. A recommendation to consider hypofractionation in intermediate-risk patients is provided. Patients with cN1 PCa should be offered a local treatment combined with long-term intensified hormonal treatment.
CONCLUSIONS AND CLINICAL IMPLICATIONS: The evidence in the field of diagnosis, staging, and treatment of localised PCa is evolving rapidly. These PCa guidelines reflect the multidisciplinary nature of PCa management.
PATIENT SUMMARY: This article is the summary of the guidelines for "curable" prostate cancer. Prostate cancer is "found" through a multistep risk-based screening process. The objective is to find as many men as possible with a curable cancer. Prostate cancer is curable if it resides in the prostate; it is then classified into low-, intermediary-, and high-risk localised and locally advanced prostate cancer. These risk classes are the basis of the treatments. Low-risk prostate cancer is treated with "active surveillance", a treatment with excellent prognosis. For low-intermediary-risk active surveillance should also be discussed as an option. In other cases, active treatments, surgery, or radiation treatment should be discussed along with the potential side effects to allow shared decision-making.
引用
- Cornford P, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2024. PMID: 38614820. doi:10.1016/j.eururo.2024.03.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。